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Available online 13 May 2017Mitochondrial dysfunction increases oxidative stress and depletes ATP in a variety of disorders. Several antioxi-
dant therapies and drugs affecting mitochondrial biogenesis are undergoing investigation, although not all of
them have demonstrated favorable effects in the clinic. We recently reported a therapeutic mitochondrial drug
mitochonic acid MA-5 (Tohoku J. Exp. Med., 2015). MA-5 increased ATP, rescued mitochondrial disease ﬁbro-
blasts and prolonged the life span of the disease model “Mitomouse” (JASN, 2016). To investigate the potential
of MA-5 on various mitochondrial diseases, we collected 25 cases of ﬁbroblasts from various genetic mutations
and cell protective effect of MA-5 and the ATP producing mechanism was examined. 24 out of the 25 patient ﬁ-
broblasts (96%) were responded to MA-5. Under oxidative stress condition, the GDF-15 was increased and this
increase was signiﬁcantly abrogated by MA-5. The serum GDF-15 elevated in Mitomouse was likewise reduced
by MA-5. MA-5 facilitates mitochondrial ATP production and reduces ROS independent of ETC by facilitating
ATP synthase oligomerization and supercomplex formation with mitoﬁlin/Mic60. MA-5 reduced mitochondriaKeywords:
MA-5
Mitochondrial disease
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28 T. Matsuhashi et al. / EBioMedicine 20 (2017) 27–38fragmentation, restores crista shape and dynamics. MA-5 has potential as a drug for the treatment of variousmi-
tochondrial diseases. The diagnostic use of GDF-15 will be also useful in a forthcoming MA-5 clinical trial.©2017 TheAuthors. Publishedby Elsevier B.V. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mitochondrial diseases are life-threatening and progressive because
of increased oxidative stress and depleted ATP are serious problems that
can cause cell death (Schapira, 2012; Vafai and Mootha, 2012).
However, they are largely untreatable because of the lack of effective
drugs (Avula et al., 2014; Gorman et al., 2016). Recently, we invented
and reported a mitochondria-homing drug, Mitochonic acid-5 (MA-5)
(4-(2,4-diﬂuorophenyl)-2-(1H-indole-3-yl)-4-oxobutanoic acid), that
both increases cellular ATP and protects mitochondrial patients' ﬁbro-
blasts from cell death (Suzuki et al., 2015, 2016). MA-5 also upregulated
cardiac and renal respiration in the mitochondrial disease model
Mitomouse (Nakada et al., 2001), resulting in a prolongation of survival
(Suzuki et al., 2016). In the reports, we examined the effect of MA-5 in
one case each of Leigh syndrome, myopathy encephalopathy lactic aci-
dosis and stroke-like episodes (MELAS), Kearns-Sayre syndrome (KSS)
and Leber hereditary optic neuropathy (LHON) patient ﬁbroblasts.
However, within the mitochondrial diseases, there are many gene mu-
tations of electron transfer complex (ETC) and ATP synthase that have
a deleterious impact on their functions (Koopman et al., 2012). There-
fore, the aim of this study is to examine the general effectiveness of
MA-5 across a range of mitochondrial disease ﬁbroblasts with a variety
of genetic mutations. In addition, for designing a clinical study of a drug,
effective biomarkers are necessary to enable the selection of responsive
participants, optimization of the dosing regimens and assessment of the
treatment efﬁcacy (Hurko, 2013). Recently, it was reported that growth
differential factor 15 (GDF-15)may be an effectivemarker of mitochon-
drial damage and thus useful in the diagnosis of mitochondrial diseases
(Fujita et al., 2014; Yatsuga et al., 2015). However, the relation between
therapeutic intervention and the GDF-15 level has not been well deter-
mined. We therefore examined the GDF-15 level when mitochondria
have being damaged by oxidative stress and whether it would be re-
duced byMA-5.We also examined the effectiveness of GDF-15 as a ther-
apeutic marker in a mitochondrial disease model “Mitomouse”. In our
previous report, MA-5 was shown to increase the cellular ATP level
with the mechanism apparently carried out by its mitochondrial mem-
brane binding protein,mitoﬁlin/Mic60 (Suzuki et al., 2016, 2015). How-
ever, the precise mechanism underlying the increase in ATP has not
been elucidated yet. To identify the mechanism of action of MA-5, we
examined the bioenergetic analysis of mitochondria and examined the
formation of a supercomplex of ATP synthase with mitoﬁlin/Mic60. Be-
cause energetic change ofmitochondria has a potent inﬂuence onmito-
chondrial morphology and kinetics (Giedt et al., 2012; Kumari et al.,
2016), we also evaluated the shape and movement of mitochondria
with or without MA-5 in patient ﬁbroblasts.
2. Materials and Methods
2.1. Synthesis of MA-5
MA-5, 4-(2,4-diﬂuorophenyl)-2-(1H-indole-3-yl)-4-oxobutanoic
acid was chemically synthesized at Okayama University of Science as
previously reported (Suzuki et al., 2015). BSO (L-Buthionine-(S,R)-
sulfoximine was purchased fromWako Pure Chemical Industries).
2.2. Human Skin Fibroblasts
Fibroblasts obtained by skin biopsy of mitochondrial disease pa-
tients were collected in Kanagawa Children's Medical Center (KCMC),Jichi Medical University and Tohoku University Hospital under the ap-
proval of the Ethical Committee of TohokuUniversity.Written informed
consent was obtained from all of the patients.
Among 25mitochondrial disease cases we examined, case 5 (Leigh),
case 11 (MELAS), case 17 (LHON) and case 20 (KSS) are examined as
previous reported (Suzuki et al., 2015). In the cell viability experiments,
ﬁbroblasts were cultured in 1.0 g/L low-glucose DMEMwith 10% FBS at
37 °C in 5% CO2. Cell viability assay was performed (Suzuki et al., 2015).
The LDH level wasmeasured by cell count using LDH cytotoxicity detec-
tion kit (Takara). The levels of GDF-15 and FGF-21 were determined
using a Quantikine Human GDF-15 ELISA Kit and Quantikine Human
FGF-21 ELISA Kit (R&D Systems), respectively.
2.3. Measurement of Heteroplasmy Levels of Mitochondrial DNAMutations
Themitochondrial DNAmutation heteroplasmy level was examined
by deep sequencing of themutated regions. The primers used for ampli-
ﬁcation of the target regions of each patient ﬁbroblast are listed in Sup-
plementary Table 1. After the ﬁrst PCR ampliﬁcation, the PCR products
were subjected to the second-round PCR for attachment of the index se-
quences required for next-generation DNA sequencing on an illumine
NextSeq500 sequencer (Illumina Inc.) as described previously
(Shimbo et al., 2014; Nakayama et al., 2017). The PCR products were
read on a 150-base paired-end mode. The number of reads containing
a mutation of interest was counted using a combination of bioinformat-
ics tools (BWA, 0.7.15; Picard, 2.8.2; GATK, 3.7; https://software.
broadinstitute.org/gatk/). The heteroplasmy was expressed as a ratio
of the read number with mutation over the total read number (N105
reads) in percentage terms. We also examined the heteroplasmy level
by PCR-RFLP analysis (Supplementary Fig. 1, according the Supplemen-
tary Methods) and primers used for PCR is listed in Supplementary
Table 2.
2.4. Mitomouse
All animal experiments were approved by Tohoku University and
Tsukuba University Animal Care Committees. Mitomouse carrying
wild-typemtDNA andmutant mtDNAwith a pathogenic 4696-bp dele-
tionwas generated by our group (Nakada et al., 2001). Mitomousewere
fed with normal chow and MA-5 at 50 mg/kg body weight per day or
the vehicle corn oil for 30 days. The GDF-15 level in the Mitomouse
was measured with a Quantikine Mouse/Rat GDF-15 ELISA Kit (R&D
Systems).
2.5. Mitochondrial Function Measurement
The oxygen consumption and pHgradient of theﬁbroblasts from the
Leigh patients or normal volunteers were measured using Seahorse XF
24 (Seahorse Bioscience). Brieﬂy, cells were cultured in the assay medi-
um (70 mM sucrose, 220 mMmannitol, 10 mM KH2PO4, 5 mMMgCl2,
2 mM HEPES, 1.0 mM EGTA and 0.2% (w/v) fatty acid-free BSA,
pH 7.2) without CO2 for 60 min, then, after equilibration, cells were
measured in the three respiration rates followed by injections of three
inhibitors of mitochondrial oxidative phosphorylation (OXPHOS)
2.6. Membrane Potential Analysis of Mitochondrial Membrane
The membrane potential of mitochondria was measured with a
Mito-ID™membrane potential Cytotoxicity Kit (Enzo Life Science).
29T. Matsuhashi et al. / EBioMedicine 20 (2017) 27–382.7. The Measurement of ATP Production After Treatment with DMSO or
MA-5
Fibroblasts from a Leigh syndrome patient (Fig. 3e, left panel, Case
10 in Table 1) and a MELAS patient (Fig. 3e, right panel, Case 15 in
Table 1) were cultured in 96 well plates at 3000 cells per each well (n
= 4). The ATP level was measured 3 h after DMSO or MA-5 treatment
(10 μM) by ATP measurement kit (Toyo ink).
2.8. Blue-Native (BN) and Clear-Native (CN) PAGE
30 μg of bovine heart mitochondria were solubilized with 50 μL of
phospholipids buffer, following DMSO (0.1%) or MA-5 (100 μM) treat-
ment for 30 min on ice.
After 20min of centrifugation at 17,400 rpm at 4 °C, the pellet of mi-
tochondria was dissolved by 30 μL of 0.25%, 0.5% and 1% digitonin with
7.5 μL of Native Page sample buffer. After electrophoresis, the CN-PAGE
gel was incubated in pre-incubation buffer (270 mM Glycine and
35 mM Tris/HCl, pH 7.4) for 2 h at 37 °C. Then the gel was incubated
in assay buffer (35 mM Tris, 270 mM Glycine, 14 mM MgSO4, 0.2%
Pb(NO3)2, 8 mM ATP, pH 8.3) at 37 °C. ATP hydrolysis correlated with
the development of a white lead phosphate precipitate (Strauss et al.,
2008). For Western blot, the BN-PAGE gel was transferred to a PVDF
membrane. The membrane was incubated with the antibodies ATP5A
(ab110271, Abcam), ATP5B (ab14730, Abcam), ATP5I (16483-1-AP,
Proteintech, Japan), ATP5L (16307-1-AP, Proteintech) and mitoﬁlin
(ab137057, Abcam), and the bands were detected using the enhanced
Chemiluminescent plus system (Amersham).We conﬁrmed the protein
loading level in each lane by Western blot using VDAC1 (Abcam,
ab18988) as an internal protein marker. In addition, the same amountTable 1
The characteristics and MA-5 response in skin ﬁbroblasts from patients with mitochondrial dis
#1 Shimbo H. et al., Mol. Genet. Metab. Rep. 1: 33, 2014.
Case Disease Age Cell ID Gene mutation Protein Sensi
1 Leigh 8 THK2 m.10191TNC ND3 (+)
2 Leigh 16 THK5 (−) (−) (+)
3 Leigh 8 THK6 m.10191TNC ND3 (+)
4 Leigh 16 THK7 (−) (−) (+)
5 Leigh 0 KCMC10 m.10158TNC ND3 (+)
6 Leigh 5 KCMC14 m.8993TNG ATPase6 (+)
7 Leigh 2 KCMC15 p.Ala248Asp SURF1 (+)
8 Leigh 0.8 KCMC17 c.367_368del AG SURF1 (+)
9 Leigh 5 ME54–1 c.55CNT NDUFA1 (+)
10 Leigh 34 THK17 (−) (−) (+)
11 MELAS 14 KCMC9 m.3243ANG tRNA-Leu (+)
12 MELAS 14 KCMC11 m.3243ANT tRNA-Leu (+)
13 MELAS 13 KCMC12 m.586GNA tRNA-Phe (+)
14 MELAS 56 THK12 m.3243ANG tRNA-Leu (+)
15 MELAS 20 THK28 m.3243 ANG tRNA-Leu (+)
16 MELAS 9 ME07–1 m.4450GNA tRNA-Met (+)
17 LHON 18 THK8 m.11778GNA ND4 (+)
18 LHON 66 THK9 m.11778GNA ND4 (−)
19 LHON 41 THK10 m.11778GNA ND4 (+)
20 KSS 13 THK4 (−) (−) (+)
21 CPEO 15 THK23 (−) (−) (+)
22 DOA 73 THK14 c.1377_1381 delTGTAA p.Asn459Met (+)
23 Unclassiﬁed 13 THK1 (−) (−) (+)
24 Unclassiﬁed 3 THK3 (−) (−) (+)
25 Unclassiﬁed 64 THK11 (−) (−) (+)
Normal 0 THK0 (−) (−) (−)
Table shows the character of mitochondrial disease patients and the results of the cell viability a
iousmitochondrial diseases, MA-5 exhibited a cell-protective effect under the conditions of oxid
This case had the same mutation as the other two cases of LHON but was insensitive to BSO
heteroplasmy rate of each case was analyzed by NGS and PCR-RFLP. All the ﬁbroblast assay in
THK, Tohoku University hospital; KCMC, Kanagawa Children's Medical Center; ME, Jichi Medica
Lactic Acidosis, Stroke-like episodes; LHON, Leber Hereditary Optic Neuropathy; KSS, Kearns-Sa
atrophy.
The rate of mutation in Case 7 was reported previously (Shimbo et al., 2014).of mitochondria used for BN-PAGE was solubilized with 1.0% digitonin,
then electrophoresed using SDS-PAGE, and western blotting was per-
formedwith VDAC 1 antibody (ab18988, Abcam) as the loading control.
The concentration ratio of each monomer or dimer band of ATP5A was
measured using ImageJ software, and statistical analysis was performed
as shown in Fig. 4c.
2.9. Mass Spectrometry Analysis
Eluted proteins were separated on 4–12% gradient BN–PAGE gels
(Invitrogen) and stainedwith Silver. Each gel lanewas cut into gel slices,
and the proteins therein were in-gel digested with trypsin (Promega).
MALDI-TOF MS was carried out on a Voyager-De-Pro Biospectrometry
Workstation (Applied Biosystems). Mass spectra were collected in pos-
itive reﬂectronmode in amass range between 700 and4000Da. Peptide
masses were matched against the Swiss-Prot, NCBInr, and MSDB data-
bases using the MASCOTsearch engine (Matrix Sciences) with a
100 ppm mass tolerance error.
2.10. Immunoprecipitation of Mitoﬁlin/Mic60 Binding Proteins
The HEK293 cells stably expressing Flag-IMMT generated by Flip-in
T-Rex system (1 mL) and the control cells (generated by pcDNA5/FRT/
TO vector only) (1 mL) were homogenized in SHE buffer (10 mM
Hepes pH 7.4, 0.21 M mannitol, 0.07 M sucrose, 0.1 M EDTA, 0.1 M
EGTA, 0.15 mM spermine, 0.75 mM spermidine) and centrifuged for
10min at 3000 rpm. The pellets were rinsedwith SHE buffer and centri-
fuged once more. The pellets were then extracted in 1 mL of extraction
buffer (50 mMHEPES pH 7.4, 0.3 M NaCl, 0.2% NP40) by sonication and
the extracts were clariﬁed by centrifugation at 12,000 rpm for 30min ateases.
tivity for BSO Effect of MA-5 GDF-15 (pg/mL) FGF-21 (pg/mL)
Mutation
rate (%)
NGS RFLP
(+) 4555.7 3230
(+)
(+) 2051.5 3241.8 17
(+) 1072.4 732.8
(+) 82 87.9
(+)
(+) 78#1
(+)
(+) 671.2 149.2
(+) 1033.7 1192.7
(+) 21 17.2
(+) 38 49.4
(+)
(+) 5505.7 1708.1 81 85.4
(+) 1929.7 784.8 48 49
(+) 784.5 205.8
(+) 520.1 80.9 100 100
(−) 2647 434.9 100 100
(+) 1322.4 912.1 97 82
(+) 2900.2 2088.5
(+) 2461.7 790.8
(+) 1310.2 215.8
(+) 4910 789.9
(+) 1071.4 66.5
(+) 4428 396.4
(−)
ssay using skin ﬁbroblasts with mitochondrial diseases. In 24 out of 25 (96%) cases of var-
ative stress induced by BSO treatment. One case of LHONwas insensitive to BSO (case 18).
, so we were unable to assess the effect of MA-5 on the ﬁbroblasts. The mitochondrial
this table was performed under 12 passages.
l University Children's Medical Center; MELAS, Mitochondrial myopathy, Encephalopathy,
yre syndrome; CPEO, Chronic progressive external ophthalmoplegia, DOA, Domestic optic
30 T. Matsuhashi et al. / EBioMedicine 20 (2017) 27–384 °C. The nuclear extracts were incubated with anti-ﬂag antibody M2
beads for 4 h in the presence of RNase A (10 mg/mL) and DNase I
(10 mg/mL) at 4 °C. After washing three times with washing buffer
(0.15 M NaCl, 0.1% NP-40, 50 mM HEPES pH 7.4) and once with PBS,
the binding proteins were eluted by 40 mL of 0.1 M glycine buffer
pH 3.0. The elutes were neutralized by 1 M Tris-HCl buffer pH 9.5 and
suspended in SDS-PAGE sample buffer. The samples were boiled for
5 min and were resolved by SDS-PAGE. The gel was stained using a
Wako Mass silver stain kit. Gel slippage was reduced by 100 mM of
DTT and alkylated by 100 mM idoacetamide. After washing, the gels
were incubated with trypsin overnight at 30 °C. Recovered peptides
were desalted by Ziptip c18 (Millipore). Samples were analyzed by
nanoLC/MS/MS systems (DiNa HPLC system KYA TECH Corporation/
QSTAR XL Applied Biosystems). Mass data acquisitions were piloted
by Mascot software.
2.11. Elution Proﬁle of on Size-Exclusion Chromatography
MA-5 treatment (10 μM, 1 h) and untreated HEC293T cell extracts
were separated on a Superose™ 6 (GE Healthcare). The proteins of
each fraction were then separated by SDS-PAGE and analyzed byWest-
ern blotting with an anti-mitoﬁlin/Mic60 antibody and anti-ATP5A an-
tibody. The Superose™ 6 column was calibrated by the standard
proteins (Thyroglobulin 669 kDa, β-amylase 200 kDa, carbonic
anhydrase 29 kDa) and Blue dextran (2,000,000 kDa).
2.12. Microscopic Imaging
For live-cell imaging microscopy, culture dishes with ﬁbroblasts
from Leigh syndrome patient following Mitotracker (green) staining
were placed into a LSM780 Zeiss confocal microscopy system equipped
with incubation system S (Carl Zeiss). ZEN2012 software (Carl Zeiss)
was used to analyze the trajectory of each mitochondrion.
For super resolution images, cells from a Leigh syndrome patient
were stained with MitoRed (shown in red) and the nucleus counter-
stained with Hoechst3342 (shown in blue). The samples were then
placed into a Nikon N-SIM super resolution microscopy system
(Nikon). Images were acquired and the data analyzed using NIS-Ele-
ments with N-SIM analysis software (Nikon). Electron microscopic
analysis was performed as previously reported (Ogata et al., 2015).
2.13. Statistical Analysis
The data are expressed as means ± SEM. Comparisons were made
using unpaired two-tailed Student's t-tests, two-way ANOVA and
Tukey-Kramer test, as appropriate (JMP Pro 12 software). In the com-
parison of GDF-15 in the Mitomouse, non-parametric Wilcoxon rank
sum test was used. A p value of b0.05 was considered signiﬁcant (#p b
0.05, ##p b 0.01, ###p b 0.001, *p b 0.05, **p b 0.01, ***p b 0.001).
3. Results
3.1. Cell-Protective Effect of MA-5 Independent of Their Genetic
Backgrounds
We have reported that MA-5, a newly synthesized derivative of the
plant hormone indole acetic acid, improved the cell survival of ﬁbro-
blasts from 4 patients with Leigh syndrome, MELAS, LHON and KSS
(Suzuki et al., 2015). However, mitochondrial diseases are composed
of a heterogeneous group of geneticmutations encoded by either nucle-
ar or mitochondrial DNA (Pieczenik and Neustadt, 2007; Vafai and
Mootha, 2012). This heterogeneity hampers both diagnosis and treat-
ment. To evaluate the general efﬁcacy of MA-5 in variousmitochondrial
diseases, we collected 25 ﬁbroblasts from variousmitochondrial disease
patients with a wide variety of genetic backgrounds (Table 1). Recently,
we (Suzuki et al., 2015) and another group (Enns et al., 2012) reportedthat the evaluation of cell viability using a glutathione synthesis inhibi-
tor L-buthionine-(S,R)-sulfoximine (BSO), which reduces glutathione
synthesis and increases the ROS level so as to result apoptosis and cell
death, is a useful method for evaluatingmitochondrial damage in mito-
chondrial disease patient ﬁbroblasts. In addition, we measured the LDH
level in the culture medium to further determine the cell viability. At
ﬁrst, we checked the effect of BSO in normal ﬁbroblasts. In normal
skin ﬁbroblasts, the cell viability was unaffected but the LDH level was
signiﬁcantly increased, suggestingmitochondrial damage. This elevated
LDH level was reduced by MA-5 in a dose-dependent manner (Supple-
mentary Fig. S1a). In patient ﬁbroblasts, 24 of 25 cases (96%) were sen-
sitive to BSO and responded to MA-5 irrespective of their genetic
backgrounds (Table 1). All of the Leigh (10 cases, Fig. 1a and Supple-
mentary Fig. S1b–k) and MELAS patient ﬁbroblasts (6 cases, Fig. 1b
and Supplementary Fig. S1l–q) were sensitive to BSO, and MA-5
protected against BSO-induced cell death in a dose-dependent manner.
Reciprocally, the LDH level of BSO-treated patient ﬁbroblasts was signif-
icantly increased and this BSO-induced increase was abrogated by MA-
5. In 3 cases of LHON, 2 cases were sensitive to BSO and that MA-5
protected against cell death (Fig. 1c and Supplementary Fig. S1r–t).
MA-5 was ineffective in the other case of LHON (Case 18). This case
had the samemutation as the other two cases of LHON but was insensi-
tive to BSO, so wewere unable to assess the effect of MA-5 on the ﬁbro-
blasts. We found that all the rest of the 6 cases (1 each case of KSS, DOA
and chronic progressive external ophthalmoplegia (CPEO), and 3 cases
of genetically unidentiﬁed mitochondrial diseases) were also sensitive
to BSO and MA-5 protected against cell death (Supplementary Fig.
S1u–z). These data suggest thatMA-5 induces a cell-protective effect in-
dependently of the genetic background in a variety of mitochondrial
diseases. We also examined the mitochondrial DNA heteroplasmy
levels. Among 25 cases, 13 cases have affected mitochondrial DNA mu-
tation and we can conﬁrm heteroplasmy level of 10 cases and men-
tioned in Table 1 and Supplementary Fig. S2. The heteroplasmy level
was varied at 15–97%.
3.2. GDF-15 Predicts MA-5-Responsiveness and Prognosis
When planning a clinical study with a drug ﬁst-in-human, effective
biomarkers enable the selection of responsive participants, optimization
of the dosing regimens and assessment of the efﬁcacy of the drug
(Hurko, 2013). In mitochondrial diseases, the lactate to pyruvate (L/P)
ratio, FGF-21 (Suomalainen et al., 2011) and GDF-15 (Suomalainen et
al., 2011; Yatsuga et al., 2015) are candidates for diagnosing and evalu-
ating the progression in mitochondrial diseases. We measured the
serum level of GDF-15 and FGF-21 in 17 available patients with mito-
chondrial diseases. The average serum concentration of GDF-15 was
2063.26 ± 392.53 pg/mL, representing a signiﬁcant increase compared
with normal volunteers (Fig. 2a, left). The serum levels of FGF-21 in 17
patients with mitochondrial diseases were 1001.24 ± 252.40 pg/mL,
with many values overlapping those of normal volunteers (Fig. 2a,
right). In addition, there was no signiﬁcant correlation between the
GDF-15 level and FGF-21 level, suggesting that GDF-15 is a better mark-
er for predicting the mitochondrial condition in our patients examined
(Fig. 2b).
We next measured the GDF-15 and FGF-21 levels in the culture me-
dium of ﬁbroblasts from patients to further evaluate whether GDF-15 is
an effective marker for estimating themitochondrial damage. The GDF-
15 level was signiﬁcantly increased by BSO in relationship with the ex-
posure time andwas signiﬁcantly increased at 72 h (Fig. 2c). In contrast,
FGF-21 was unchanged. We next examined the relationship between
the cell-protective effect of MA-5 and the level of GDF-15. In normal ﬁ-
broblasts, the cell viability was not changed by BSO treatment but the
level of GDF-15 in the culture mediumwas signiﬁcantly increased, sug-
gesting incipient mitochondrial damage (Fig. 2d). This BSO-induced el-
evation of GDF-15 in normal ﬁbroblasts was normalized by MA-5.
Subsequently, we also measured the GDF-15 in the culture medium of
Fig. 1.Cell-protective effect ofMA-5 in Leigh syndrome,MELAS and LHONasmeasuredby cell viability assay and the level of LDH in the culturemedium. (a) A summary of 10 cases of Leigh
syndrome (from case 1 to case 10 in Table 1). (b) A summary of 6 cases of MELAS (from case 11 to case 16 in Table 1). (c) A summary of 2 cases of LHON (case 17 and 19 in Table 1; n=2).
MA-5 exerted a cell protective effect against oxidative stress in a dose-dependentmanner (MA-5 concentration is from0.1 to 30 μM). The ﬁgure on the left is the cell viability assay and on
the right the level of LDH in the culturemedium (n=10). The data represent themean+ SEM. ###p b 0.001 (two-way ANOVA and Tukey post hoc test versus Control), ***p b 0.001 (two-
way ANOVA and Tukey–Kramer test versus BSO with DMSO). The red square indicates signiﬁcantly increased or decreased compared with DMSO.
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We chose a BSO concentration that reduced the cell survival to approx-
imately 50%. The GDF-15 level was clearly increased by BSO treatment
and MA-5 signiﬁcantly decreased the up-regulated GDF-15 level in the
ﬁbroblasts from Leigh syndrome (7 of 10 cases, Fig. 2e), MELAS (5 of 6
cases, Fig. 2f), LHON (2 of 3 cases, Fig. 2g), KSS (1 of 1 case), DOA (1 of
1 case), CPEO (1 of 1 case) and unidentiﬁed mitochondria disease (3
of 3 cases). These data further suggest that the GDF-15 level is a useful
biomarker that predicts the cell protective effect of MA-5.
3.3. MA-5 Reduced GDF-15 Level in the Mitomouse
Recently,we reported thatMA-5 improved the cardiac and renal res-
piration and prolonged survival in the “Mitomouse”, an animal carrying
a deleted mitochondrial DNA mutation that which show abnormalities
of cardiac conduction system, extraocular muscle paralysis, retinitis
pigmentosa, and severe renal failure, partly similar to Kerns-Sayre syn-
drome (Nakada et al., 2001; Suzuki et al., 2016).
Recently, there are several reports that GDF-15 may be an effective
marker of mitochondrial damage and thus useful in the diagnosis ofmitochondrial diseases (Fujita et al., 2014; Yatsuga et al., 2015), but
the relation between therapeutic intervention and the GDF-15 level
has not been well determined and reported. Therefore, we measured
the serum level of GDF-15 in the control or MA-5-treated Mitomouse.
Before treatment, we conﬁrmed that the genomic mutation rate in the
tail was at the same level (~50%) and the serum pyruvate level was in-
creased in all of the Mitomouse. The average level of GDF-15 in
Mitomouse was 1064.3 ± 391.8 pg/mL in DMSO group and 919.4 ±
391.8 pg/mL in DMSO group (there was no statistically difference)
that is signiﬁcantly high compared to the normal mouse (77.0 ±
25.24 pg/mL, according the instruction), suggesting the pathologic con-
dition of the Mitomouse.
In the control group (n=11), the GDF-15 level was increased in 8
mice (72.7%) and decreased in 3 mice (27.3%) (Fig. 2h, left). In the
MA-5 treatment group (n = 17), the GDF-15 was increased in 6
mice (35.3%) and decreased in 11 mice (64.7%), indicating that MA-
5-treatment signiﬁcantly decreased the GDF-15 level compared
with the control (Fig. 2h, p = 0.0369). These data further suggest
that MA-5 works not only in vitro but also in vivo and that GDF-15
could be a good marker for evaluating the therapeutic efﬁcacy of
Fig. 2.Measurement of the level of GDF-15 and FGF-21 in patient's serum and in the supernatant of cultured mitochondrial patient's ﬁbroblasts. (a) The level of GDF-15 and FGF-21 in 17
mitochondrial disease patients' serum. **p b 0.001 (p=0.0082, non-parametricWilcoxon rank sum test; n=17). (b) The relationship between GDF-15 and FGF-21 in themitochondrial
disease patients' serum (n=17). (c) GDF-15 and FGF-21 time course assay after BSO treatment in Leigh disease ﬁbroblasts (Case 5 in Table 1) **p b 0.01 (unpaired two-tailed Student's t-
test versus 0 h). The data are expressed as mean ± SEM. The measurement of normal (d), Leigh (e), MELAS (f), and LHON (g) ﬁbroblasts in the cell viability assay (left panel) after 72 h-
DMSO application as control and 72 h-MA-5 at 10 μMtreatment under 24 h-BSO treatment-induced oxidative stress in eachmitochondrial disease. The levels of GDF-15 (right panel)were
measured in the samemanner in cultured ﬁbroblast medium. #p b 0.05, ##p b 0.01, ###p b 0.001 (two-way ANOVA and Tukey–Kramer test versus Control), *p b 0.05, **p b 0.01 and ***p b
0.001 (two-way ANOVA and Tukey–Kramer test versus BSO+DMSO; normal ﬁbroblast n=1, Leigh syndrome n=10,MELAS n=6 and LHON n=2). Data are expressed as themean±
SEM. The vertical axis is in logarithmic notation. (h) The level of GDF-15 inMitomousewithDMSO treatment (left,n=11) andMA-5 (right, n=17), respectively. Note that inMA-5group,
GDF-15 level was signiﬁcantly decreased (p= 0.0369, non-parametric Wilcoxon rank sum test).
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drial disease.
3.4. Mitochondrial Bioenergetic Analysis
We next measured the mitochondrial bioenergetic function
governing the oxygen consumption rate (OCR) and extra-cellular acid-
iﬁcation rate (ECAR) (Pelletier et al., 2014; Rose et al., 2014). The basal
and oligomycin-inhibited cellular OCR in the normal and Leighsyndrome ﬁbroblasts were at the same level. After Carbonyl cyanide-
p-triﬂuoromethoxyphenylhydrazone (FCCP, a mitochondrial uncou-
pler) treatment, the OCR values were signiﬁcantly increased in both,
but the increase was appreciably smaller in the Leigh syndrome ﬁbro-
blasts because of the genetic impairment in ETC activity Fig. 3a, left).
The overall ECAR values were appreciably higher in the Leigh syndrome
ﬁbroblasts, suggesting that glycolysis was activated to compensate for
the genetic impairment in mitochondrial OXPHOS (Fig. 3a, right). In
such cells, MA-5 treatment did not affect the FCCP-stimulated OCR
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tracellular mitochondrial respiratory activity and glycolysis in Leigh
syndrome ﬁbroblasts. These data suggest that MA-5 may not affect in-
tracellular mitochondrial respiratory activity and glycolysis in Leigh
syndrome ﬁbroblasts.
To further examine the mitochondrial function, the mitochondrial
membrane potential andmitochondrial ROS formation in theﬁbroblasts
were monitored. The mitochondrial membrane potential was not
changed by BSO treatment both in normal and Leigh syndrome ﬁbro-
blasts (Fig. 3c). In addition, MA-5 did not change the mitochondrial
membrane potential in both ﬁbroblasts. In contrast, mitochondrial
ROS generation was signiﬁcantly reduced by MA-5 (Fig. 3d). These
data further suggest that MA-5 reduces mitochondrial ROS generation
independently of the membrane potential.Fig. 3. Effects of MA-5 onmitochondrial respiration. (a) Bioenergetic assay with normal and Lei
assay with ﬁbroblasts from Leigh patient treatment with DMSO or MA-5 (10 μM) in compari
ﬁbroblast (left) and Leigh syndrome ﬁbroblasts (right). (d) Mitochondrial ROS production wa
(right) under the oxidative stress induced by BSO-treatment. (e) MA-5 increased the ATP leve
(10 μM) for 3 h. *p b 0.01 (unpaired two-tailed Student's t-test versus DMSO).However, when we measured the ATP levels in Leigh's syndrome
(Case 10 in Table 1) and MELAS (Case 15 in Table 1) patient ﬁbroblasts,
it would be revealed that the APT level in patientﬁbroblastswere signif-
icantly increased by treatmentwithMA-5 (Fig. 3e). These results further
suggest thatMA-5 facilitatesmitochondrial ATP production and reduces
mitochondrial generation independently of OXPHOS/ETC chemiosmotic
machinery (Suzuki et al., 2016).
3.5. MA-5 Increased Supercomplex Formation of ATP Synthase
More than 90% of ATP production is made by OXPHOS. Based on
chemiosmotic theory, the movement of ions across an electrochemical
potential is able to provide the energy needed to produce ATP
(Mitchell, 1961; Pieczenik and Neustadt, 2007). However, as shown ingh syndrome ﬁbroblasts in comparison with OCR (left) and ECAR (right). (b) Bioenergetic
son with OCR (left) and ECAR (right). (c) Mitochondrial membrane potentials in normal
s reduced by MA-5-treatment of normal ﬁbroblasts (left) and Leigh syndrome ﬁbroblasts
l of ﬁbroblasts of Leigh syndrome (left) and MELAS (right) treated with DMSO and MA-5
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pendently of the patient mutations in OXPHOS complex I, IV and
ATPase6 that gene mutation that have been found in approximately
20% of people with Leigh syndrome. As we reported, MA-5 completely
rescued cell viability compromised by the addition of the ECT inhibitors
rotenone (complex I),malonate (complex II), antimycin A (complex III),
azide (complex IV) and oligomycin (complex V, Fo part), aswell as FCCP
(Suzuki et al., 2015). Our data had indicated thatMA-5 does not exert its
function independently of mitochondrial ETC or the increasing mem-
brane potential. One of the possible mechanisms of action of MA-5 is
an effect on the oligomerization of ATP synthase (Suzuki et al., 2016).
The oligomerization of ATP synthase is essential for the maintenance
of cristae junctions (Habersetzer et al., 2013). In addition, the oligomer-
ization of ATP synthase increases the local pH gradient and membrane
potential, and optimizes ATP synthesis without changing thewhole mi-
tochondrial membrane potential (Strauss et al., 2008).
To clarify the mechanism by which MA-5 accelerates ATP synthesis,
we examined the supercomplex formation of ATP synthase by in-gel vi-
sualization of ATP synthesis using clear native-PAGE (CN-PABE). Fig. 4a
shows the characteristic “ladder” of the bands representingmonomeric,
dimeric and multimeric complexes of ATP synthase, and the intensity
represents the resulting production of ATP (Strauss et al., 2008). The di-
meric andmultimeric ATPase complexes formation and ATP production
were signiﬁcantly facilitated by MA-5 (n= 3) indicating that MA-5 di-
rectly increased ATP production. In addition, increasing the detergent
concentration (0.5 to 1% digitonin) resulted in a decrease of the dimer
and a corresponding increase in the monomeric form, as reported
(Arnold et al., 1998) (Fig. 4a). Western blot analysis also revealed that
MA-5 signiﬁcantly increased the intensity of the dimer band and the
higher complexes of the ATP5A compared with the DMSO treated
group (Fig. 4b).We also conﬁrm this by AR5B andmitoﬁlin/Mic60 anti-
bodies (Supplementary Fig. S4). The intensity of the dimer band was
also decreased and that of the monomer band was increased by the in-
crement of the detergent concentration, conﬁrming that MA-5 facili-
tates the dimeric formation of ATPase. To compare the intensity of
each of the monomer and dimer bands, we further performed SDS-
PAGE under a reducing condition and western blotting was performed
by VDAC1 as a mitochondrial internal marker to conﬁrm the loading
protein level. We found that the intensity of the MA-5-treated dimer
bands standardized with VDAC1 was signiﬁcantly increased compared
with the DMSO-treated group, while the intensity of the monomer
bands of the MA-5-treated group was not signiﬁcantly changed com-
pared with the bands of the DMSO-treated group (representing 0.25%
digitonin panle, Fig. 4c). These data further conﬁrmed that MA-5 facili-
tates the dimer formation of ATPase.
It was reported that the oligomerization of ATP synthase depends on
the interaction of two subunits of the Fo portion, subunit e (Su e) and
subunit g (Su g). These subunits are involved in generating the mito-
chondrial cristae morphology and the assembly of ATP synthase oligo-
mers, thus controlling mitochondrial biogenesis (Arnold et al., 1998;
Bornhovd et al., 2006; Habersetzer et al., 2013). Recently, it was also re-
ported that mitoﬁlin/Mic60 interacts with the Su e and Su g subunits
and regulates ATP production (Mun et al., 2010; Rabl et al., 2009).
Therefore, we next performed Western blot analyses using blue native
PAGE (BN-PAGE, Fig. 4d). Western Blot analysis of BN-PAGE revealed
that ATP5A (F1 α subunit) and ATP5B (F1 β subunit) were speciﬁcally
detected at the same molecular sizes as the monomer, dimer and
multimer complexes of the ATP synthase, and MA-5 also enhanced the
intensity of ATP5A and ATP5B. In addition, Western blot against
mitoﬁlin/Mic60, ATP5I (Su e) and ATP5L (Su g) revealed that the
bands of the dimer and multimer were also increased by MA-5. These
data suggest that MA-5 enhances the supercomplex formation among
ATP synthase, mitoﬁlin, Su e and Su g.
To further determine the component of the ATP supercomplex en-
hanced by MA-5, we examined bands that were increased in intensity
by MA-5, digesting them with trypsin and analyzing the peptides withLC/MS/MS. All the bands that were increased in intensity by MA-5
contained ATP5A, ATP5B and mitoﬁlin/Mic60 (Fig. 4e). In Band 1, the
complex I components, complex V components and SLC25A5/SLC25A6
proteins were determined. In Band 2, the complex I components, com-
plex V components and SLC25A5 proteins were determined. In Band
3, the complex I components, complex IV component and SLC25A4 pro-
teins were determined. In addition, these complexes contained ADP/
ATP carrier 1, 2, 3 (SLC25A4, SLC25A5, SLC25A6, respectively). Themito-
chondrial ADP/ATP carrier imports ADP from the cytosol and exports
ATP from the mitochondrial matrix, which are key transport steps
for oxidative phosphorylation and a component of supercomplex
(Nuskova et al., 2015). We also examined the protein-protein interac-
tion with mitoﬁlin/Mic60. Proteins bound to Flag-tagged mitoﬁlin/
Mic60 were precipitated and examined. As shown in Fig. 4f, ﬂag-tagged
mitoﬁlin/Mic60 signiﬁcantly bound ATP5A and ATP5B as well as ATP/
ADP carriers. SAM50, an outer membrane protein, was also precipitated
as supercomplex component (Koob and Reichert, 2014) and the
mitoﬁlin/mitochondrial inner membrane organizing system (MINOS)
complex (Koob and Reichert, 2014), both of which determine cristae
morphology.
To further address the supercomplex formation induced by MA-5,
change in the size of the ATP synthase complex was examined. In the
gel ﬁltration analysis, ATP5A and mitoﬁlin/Mic60 co-migrated as a
large protein complex and displayed an apparent molecular weight of
approximately 1 MDa (Fig. 4g). The fractions containing ATP5A
(upper) andmitoﬁlin/Mic60 (lower) were shifted to the higher fraction
size by the application of MA-5. In both, the band intensity of smaller
size was decreased by MA-5 treatment compared to DMSO treatment.
These results suggest that MA-5 has a potent capacity to assemble into
a supercomplex.
3.6. MA-5 Restored Damaged Cristae Morphology
Because the mitochondrial cristae shape determines both respirato-
ry chain supercomplex assembly and respiratory efﬁciency, and the
cristae shape and ATPase dimers are linked to ensure the optimal bioen-
ergetic competence of mitochondria (Paumard et al., 2002), we exam-
ined the electron micrograph of ﬁbroblasts from Leigh syndrome
patient.
Under stress condition, mitochondrial ﬁssion occurs and the reticu-
larmitochondria break into short, round pieces, a process deﬁned asmi-
tochondrial fragmentation. Accordingly, we investigated whether the
protective effects ofMA-5 aremediated by a prevention ofmitochondri-
al fragmentation. As seen in Fig. 5a, the reticularity of themitochondrial
network was broken into small, round-shaped mitochondrial pieces
after BSO exposure. Treatment with MA-5 restored the mitochondrial
tubular network in BSO-exposed cells. We measured a cross-sectional
area of mitochondria in the patient ﬁbroblasts to determine the effects
of BSO exposure on mitochondrial morphology and the degree of mito-
chondrial network branching. The recovery of the calculated average
cross-sectional area was observed to be signiﬁcant in the MA-5 treated
group compared with BSO treatment alone.
Themitochondrial cristae shape also determines both the respirato-
ry chain supercomplex assembly and respiratory efﬁciency, and the
cristae shape and ATPase dimers are linked to ensure the optimal bioen-
ergetic competence of mitochondria (Paumard et al., 2002).
We further examined by electron micrograph of ﬁbroblasts from
Leigh syndrome patient (Fig. 5b). The mitochondrial cristae in the pa-
tientﬁbroblastswere enlarged and shortened to the extent that the cris-
tae junctions were loose. On the other hand, MA-5 administration
changed the cristae shape to become thinner and longer. The maximal
length/width of MA-5 treated mitochondrial cristae was signiﬁcantly
increased compared to the control (Fig. 5b, p b 0.05, n= 100, see also
Supplementary Fig. S4). These data further suggest that MA-5 regulates
mitochondrial respiratory efﬁciency by changing the shape of the cris-
tae in biological membranes.
Fig. 4.MA-5 accelerated ATP production with the ATP synthase dimer resulting in supercomplex formation. (a) In gel ATP synthase activity. Native gel of whole, solubilized bovine heart
mitochondria with two different concentrations of digitonin (0.5% or 1.0%) stained for ATP synthesis activity. The bands corresponding to the ATP synthase monomer and dimer were
indicated by arrowheads. Note that MA-5 increased the intensity of ATPase dimer and multimer formation. (b) Western blotting analysis of Blue-Native gels. The same amounts of
isolated mitochondria were treated with three different concentrations of digitonin (0.25%, 0.5% and 1%) and treated with DMSO or MA-5. The resultant protein was electrophoresed
and transferred on a membrane. Antibody against ATP5A was used. (c) Comparison with the western blotting densitometric analysis on BN-PAGE representing 0.25% digitonin panle.
The monomer (left panel) and dimer (right panel) bands were standardized by VDAC1, which is the loading control on SDS-PAGE. (d) Western blotting analysis of Blue-Native gel
treated with DMSO and MA-5 with ATP5A, ATP5B, ATP5I (e), ATP5L (g) and mitoﬁlin/Mic60 antibodies. (e) The LC/MS analysis of the supercomplex components enhanced by MA-5
on BN-PAGE. (f) Putative mitoﬁlin/Mic60-binding proteins identiﬁed by afﬁnity chromatography and mass spectrometry (Kanno et al., 2007). (g) Elution proﬁle of MA-5 treatment or
non-treatment IMMT and ATP5A on size-exclusion chromatography. MA-5 treatment (10 μM, 1 h) and non-treatment HEC293T cell extracts were separated on a Superose™ 6 (GE
Healthcare). Proteins of each fraction were then separated by SDS-PAGE and analyzed by western blotting with an anti-IMMT antibody and anti-ATP5A antibody. After MA-5
treatment, the fractions containing ATP5A (upper) and mitoﬁlin/Mic60 (lower) were shifted to the higher fraction size.
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Fig. 5. (a) MA-5 improvedmitochondrial fragmentation. The structural change in mitochondria obtained using super resolution microscopic imaging of the control (upper left), BSO+DMSO
(upper right) and BSO+MA-5 (lower) ﬁbroblasts (BSO 30 μM, DMSO 0.1% andMA-5 10 μM). ***p b 0.001 (unpaired two-tailed Student's t-test versus BSO+DMSO; right graph). (b) MA-5
improved cristae length. Note that the cristae were damaged by BSO and that MA-5 lengthened and tightened the cristaemorphology. Arrowhead indicated the cristae. The ratio of the cristae
length and width was calculated (n= 100). *p b 0.05, **p b 0.01 and ***p b 0.001(two-way ANOVA test versus BSO + DMSO). (c) MA-5 improved mitochondrial movement. Mitochondrial
motility of Leigh syndrome ﬁbroblasts (Case 6 in Table 1) with BSO (left, upper) or with MA-5 (left lower) was measured. Note that the mitochondrial motility was signiﬁcantly increased
by MA-5. ***P b 0.001 unpaired two-tailed Student's t-test versus normal ﬁbroblast with BSO and Leigh syndrome ﬁbroblast treated with DMSO versus MA-5. (d) Role of the dimerization
and oligomerization of the ATP synthase by MA-5. Under a proton-limited condition such as in mitochondrial diseases, destabilization of the ATP synthase complex leads to an increase in
ﬂuidity and reduced efﬁcacy of ATP production (Bornhovd et al., 2006) (left panel). MA-5 stimulates the dimerization and oligomerization of the ATP synthase as well as ADP/ATP carrier in
cristae formation 5 and the formation of ATP synthase supercomplex may lead to a higher order organization of not only the ATP synthase but also other supracomplexes (Strauss et al.,
2008) (right panel). This enforces a strong local curvature on the membrane that act as proton traps, which may lead to effective ATP synthesis.
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It is well known that the cellular energy statemodulates the dynam-
ics of mitochondria (Giedt et al., 2012). Time-lapse imaging by Super-resolution microscopy revealed that the mitochondrial movement in
the Leigh syndrome ﬁbroblasts was signiﬁcantly slower (0.0090 ±
0.0004 μm/s) compared to normal ﬁbroblasts (0.0633 ± 0.0018 μm/s)
(Fig. 5c). MA-5 treatment signiﬁcantly improved the mitochondrial
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ages are on Supplementary Video Data 1 (DMSO) and Video Data 2
(MA-5)). These data further suggest that MA-5 improves mitochondrial
morphology and dynamics.
4. Discussion
There were several reports that the dimerization increased ATP syn-
thesis (Davies et al., 2011; Strauss et al., 2008). Recently, it is reported
that respiratory supercomplex assemblies increase in response to exer-
cise (Greggio et al., 2017). However, there has been no method to in-
crease the ATP synthase dimer formation as well as supercomplex
formation by “chemically”.
MA-5 had a cell-protective effect in 24 out of 25 cases (96%) using ﬁ-
broblasts. Among them, there were 7 genetically identiﬁed Leigh syn-
drome patients in which 3 cases had mutations (in the ND3, 1 case in
ATPase6 which mutations have been found approximately 20% of
Leigh syndrome (Ma et al., 2013), 2 cases in SURF1 (Tanigawa et al.,
2012), and 1 case in NDUFA1 (Uehara et al., 2014) genes. There were
6 patients with MELAS, among which 4 had mutations of tRNA-Leu, 1
of tRNA-Phe and 1 of tRNA-Met (D'Aco et al., 2013). We examined 3
cases of LHON disease in which the mutation was in ND4
(Amati-Bonneau et al., 2009; Lenaers et al., 2012) and 1 case of a DOA
patient with an OPA1 gene mutation (Amati-Bonneau et al., 2009). Al-
though the genetic mutations diverged widely in OXPHOS, MA-5
exerted its cell protective effect on almost all of the patients.
How does MA-5 exert an effect on various mitochondrial diseases
evenwhen the ETC system is disturbed? ATP production is typically de-
scribed based on the chemiosmotic theory that the movement of pro-
tons across an electrochemical potential difference provides the
energy needed to produce ATP (Mitchell, 1961). Although isolated mi-
tochondrial ATP synthase is fully active as a monomer, the ubiquitous
occurrence of ATP synthase oligomerization may also play a critical
role in the ATP production (Strauss et al., 2008). The MINOS complex
was recently reported tomaintainmitochondrial architecture and crista
junction integrity (Koob and Reichert, 2014). The mitochondrial cristae
act as proton traps, and the proton sink of the ATP synthase at the apex
of the compartment favors effective ATP synthesis. In addition, the olig-
omerization of ATP synthase increases the local pH gradient at the apex
and optimizes ATP synthesiswithout changing themitochondrialmem-
brane potential (Strauss et al., 2008). The oligomerization depends on
two subunits of Su e and Su g, with these two subunits involved in gen-
erating the assembly of ATP synthase oligomerization and regulating
mitochondrial biogenesis (Bornhovd et al., 2006). It was also reported
that the mitoﬁlin/Mic60 homolog Fcj1 interacts with the Su e and Su g
and affects ATP synthase oligomerization (Mun et al., 2010; Rabl et al.,
2009).
Recently, we found that MA-5 targets the mitochondrial protein
mitoﬁlin/Mic60 at the crista junction of innermembrane andpostulated
the possibility that this alters the conformation of theMINOS (Suzuki et
al., 2016). This led to the hypothesis that MA-5 may facilitate ATP syn-
thase oligomerization by interacting with the mitoﬁlin, Su e, Su g and
ATPase that form the ATPase supercomplex. As shown in Fig. 4a, MA-5
increased not only ATPase activity but also facilitated formation of the
ATP synthase monomer, with higher bands indicating active oligomers
up to a multimer. Western blot and MS/MS analyses revealed that, not
only ATP synthase, butmitoﬁlin/Mic60, Su e, Su g and various ETC com-
ponents were precipitated by MA-5 (Fig. 4b, c and d). It is reasonable
that ECT components were co-precipitated, because respiratory chain
complexes are assembled into a supercomplex (Habersetzer et al.,
2013). Gel ﬁltration analysis also supported this in that that MA-5 facil-
itated the shift of ATP synthase- andmitoﬁlin/Mic60-inclusion bands to
the highermolecular weight (Fig. 4f). The EM further revealed that MA-
5 change the structural shape of the cristae, and this may be reﬂected in
changes in the shape and dynamics of mitochondria (Fig. 5a–c). There-
fore, MA-5 may facilitate supercomplex formation and result in themaintenance of ATPase and MINOS complex integrity “chemically”.
This supercomplex formation of ATP synthase by MA-5 enables ATP
generation without any change in the membrane potential and is inde-
pendent of damaged ETC.
Our theory of ATP production does not contradict the chemiosmotic
theory. However, under proton-limited conditions or genetic mutation
has occurred in ETC genes, the mitochondrial cristae modiﬁcation and
supercomplex formation by MA-5 should prove useful for generating
the local proton gradient and producing ATP without changing the
membrane potential (graphic summary in Fig. 5d), without generating
mitochondrial ROS. It is also reported that supercomplex prevents the
excessive ROS formation from the mitochondria (Maranzana et al.,
2013). Thus, MA-5 has the potential to treat mitochondrial patients
with genetic mutations within various OXPHOS components, if F1F0
portion of ATP synthase itself is intact, as in the cases we studied.
Our data also show the potential diagnostic use of GDF-15, which
will be utilized in a forthcoming MA-5 clinical trial. There are several
discussion on which is diagnostic better between GDF-15 and FGF-21.
Lehtonen et al. reported that FGF-21 is a speciﬁc biomarker for mus-
cle-manifesting defects of mitochondrial translation, the most common
causes ofmitochondrial disease. However, GDF-15was increased also in
a wide range of non-mitochondrial conditions (Lehtonen et al., 2016).
On the other hand, Davis et al. reported that the serum GDF-15 mea-
surement may be more broadly speciﬁc for mitochondrial disease than
for muscle manifesting mitochondrial disease, in contrast to FGF-21
(Davis et al., 2016). GDF-15 concentrations were high in a variety of se-
vere disorders. However, as also mentioned by Lehtonen et al., in Leigh
syndrome or Leber hereditary optic atrophy, the FGF-21 can remain low
(Lehtonen et al., 2016). Because Mitomouse is a mouse model for Leigh
syndrome (Nakada et al., 2001), the difference of model may be the
cause of our difference between GDF-15 and FGF-21. Although GDF-15
is one of a candidate marker for mitochondrial damage, further experi-
ments will be necessary to ﬁnd a suitablemarker for predicting the clin-
ical effect of MA-5 in vivo and for further clinical study.
Finally, it is recently reported that respiratory supercomplex assem-
blies increase in response to exercise (Greggio et al., 2017). Our drug
MA-5 is an alternative exercise mimetics to increase the formation of
ATP synthase dimer and supercomplex formation chemically, important
on health and performance. It will be helpful not only mitochondrial
disease but also other mitochondria-related metabolic disorders such
as diabetes, diabetic nephropathy, cardiomyopathy, longevity etc.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.05.016.
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